Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 15/20 | 0.66 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.52 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.52 |
| ▸ | MITF | O75030 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | STAT6 | P42226 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17800867 | 0.87 | ADK (0.67) | ADKTP53DOT1LSLC29A1CYP1A2 | |
| SCHEMBL7070318 | 0.87 | HTR2B (0.69) | ADKTP53PAX8ADORA3SMN1; SMN2 | |
| SCHEMBL17800859 | 0.86 | ADK (0.80) | ADK | |
| SCHEMBL16968462 | 0.85 | DOT1L (0.71) | ADKTP53PAX8DOT1LCYP1A2 | |
| SCHEMBL16978208 | 0.85 | DOT1L (0.71) | ADKTP53PAX8DOT1LCYP1A2 | |
| SCHEMBL6426263 | 0.85 | DOT1L (0.71) | ADKTP53PAX8DOT1LCYP1A2 | |
| SCHEMBL13092047 | 0.85 | DOT1L (0.71) | ADKTP53PAX8DOT1LCYP1A2 | |
| SCHEMBL6838180 | 0.85 | ADK (0.72) | ADKTP53DOT1LSLC29A1CYP1A2 | |
| SCHEMBL17800872 | 0.85 | ADK (0.66) | ADKTP53DOT1LCYP1A2MAPK1 | |
| SCHEMBL17800848 | 0.85 | ADK (0.64) | ADKTP53DOT1LCYP1A2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9586986-B2 | Substituted 7-deazapurine ribonucleosides for therapeutic uses | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2017-03-07 | — | — | US | claimed |
| US-20160159844-A1 | NOVEL SUBSTITUTED 7-DEAZAPURINE RIBONUCLEOSIDES FOR THERAPEUTIC USES | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2016-06-09 | — | — | US | claimed |
| US-9586986-B2 | Substituted 7-deazapurine ribonucleosides for therapeutic uses | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2017-03-07 | — | — | US | disclosed |
| US-9586986-B2 | Substituted 7-deazapurine ribonucleosides for therapeutic uses | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2017-03-07 | — | — | US | disclosed |
| US-9586986-B2 | Substituted 7-deazapurine ribonucleosides for therapeutic uses | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2017-03-07 | — | — | US | disclosed |
| US-20160159844-A1 | NOVEL SUBSTITUTED 7-DEAZAPURINE RIBONUCLEOSIDES FOR THERAPEUTIC USES | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2016-06-09 | — | — | US | disclosed |
| US-20160159844-A1 | NOVEL SUBSTITUTED 7-DEAZAPURINE RIBONUCLEOSIDES FOR THERAPEUTIC USES | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2016-06-09 | — | — | US | disclosed |
| US-20160159844-A1 | NOVEL SUBSTITUTED 7-DEAZAPURINE RIBONUCLEOSIDES FOR THERAPEUTIC USES | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159844-A1 | NOVEL SUBSTITUTED 7-DEAZAPURINE RIBONUCLEOSIDES FOR THERAPEUTIC USES | NSUN2, DUT, TYMP | ADK 418/4885TP53 764/4885PAX8 950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.